Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Relay announces data for Zovegalisib (PI3Ki) plus Atirmociclib (CDK4i) Triplet Combination in late line MBC: 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line).
Plan to start a first-line phase 3 trial in 2026.”
Other articles about Breast Cancer on OncoDaily